News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)